bioAffinity Technologies, Inc.
BIAF
$4.00
-$0.74-15.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.59M | 1.45M | 1.27M | 1.85M | 2.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.59M | 1.45M | 1.27M | 1.85M | 2.21M |
| Cost of Revenue | 900.10K | 942.20K | 1.02M | 1.37M | 1.56M |
| Gross Profit | 692.70K | 503.90K | 252.90K | 485.70K | 645.40K |
| SG&A Expenses | 3.04M | 2.21M | 2.21M | 2.45M | 2.92M |
| Depreciation & Amortization | 123.70K | 113.40K | 113.20K | 154.60K | 153.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.73M | 3.74M | 3.79M | 4.48M | 5.15M |
| Operating Income | -3.14M | -2.29M | -2.52M | -2.63M | -2.95M |
| Income Before Tax | -3.13M | -5.05M | -4.03M | -2.65M | -2.97M |
| Income Tax Expenses | 3.20K | 3.20K | 29.00K | 8.70K | 0.00 |
| Earnings from Continuing Operations | -3.14M | -5.05M | -4.06M | -2.66M | -2.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.14M | -5.05M | -4.06M | -2.66M | -2.97M |
| EBIT | -3.14M | -2.29M | -2.52M | -2.63M | -2.95M |
| EBITDA | -3.01M | -2.18M | -2.31M | -2.57M | -2.79M |
| EPS Basic | -0.70 | -4.74 | -5.07 | -4.91 | -6.01 |
| Normalized Basic EPS | -0.44 | -2.96 | -3.15 | -3.06 | -3.76 |
| EPS Diluted | -0.70 | -4.74 | -5.07 | -4.91 | -6.01 |
| Normalized Diluted EPS | -0.44 | -2.96 | -3.15 | -3.06 | -3.76 |
| Average Basic Shares Outstanding | 4.47M | 1.07M | 800.70K | 541.90K | 493.30K |
| Average Diluted Shares Outstanding | 4.47M | 1.07M | 800.70K | 541.90K | 493.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |